{"filings":[{"id":91248,"accession_number":"0001104659-26-054940","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Marker Therapeutics shareholders approve increase in authorized shares from 30M to 130M","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Charter Amendment to increase authorized common stock from 30M to 130M shares (10.9M for, 1.4M against).","Proposal to revise voting threshold for share changes failed; broker non-votes prevented passage.","All five director nominees re-elected; advisory vote on executive compensation passed.","Ratification of CBIZ CPAs as independent auditor for fiscal 2026 approved by shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101221,"accession_number":"0001104659-26-031309","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics FY2025 net loss $12.2M; cash $17M; APOLLO 66% ORR in NHL","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.2M vs $10.7M in 2024; R&D spend $11.8M (down from $13.5M).","Cash $17M at Dec 31, 2025; expected to fund ops through Q4 2026 without new grants.","Phase 1 APOLLO data: 66% objective response rate in relapsed NHL, 50% complete responses.","MT-601 pancreatic cancer program to initiate in Q2 2026; Nature Medicine publication Jan 2026.","New board member Kathryn Penkus Corzo appointed Nov 2025; Cellipont manufacturing collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101220,"accession_number":"0001104659-26-012063","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"Marker Therapeutics sets 2026 annual meeting for May 1; shareholder proposals due March 9","event_type":"other_material","confidence":"high","bullets":["2026 Annual Meeting scheduled for May 1, 2026, moving more than 30 days from 2025 meeting date.","Shareholder proposals under Rule 14a-8 must be received by March 9, 2026, at company's Houston offices.","Record date and meeting details to be included in the upcoming proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117565,"accession_number":"0001104659-25-111940","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL","event_type":"earnings","confidence":"high","bullets":["Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.","Net loss $2.0M (improved from $2.3M YoY); R&D $2.3M (down from $3.5M).","APOLLO study: 66% ORR, 50% CR in 12 relapsed NHL patients; durable responses (≥6 months in 5); dose expansion ongoing.","First patient dosed in OTS RAPID study (MT-401) for AML/MDS; cGMP manufacturing pact with Cellipont.","Appointed Kathryn Penkus Corzo to Board; two ASH presentations scheduled Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2443225.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117564,"accession_number":"0001104659-25-106669","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Marker Therapeutics appoints Kathryn Penkus Corzo to Board; CEO granted 250,000 options","event_type":"leadership","confidence":"high","bullets":["Kathryn Penkus Corzo appointed to Board effective Nov 1, 2025; she brings 30+ years of biopharma leadership.","Corzo currently President/COO of bit.bio; previously Head of Oncology Cell Therapy at Takeda Ventures.","Corzo received 147,611 stock options as non-employee director compensation, vesting over 36 months.","CEO Juan Vera granted 250,000 stock options, vesting annually over 4 years under the 2020 Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117563,"accession_number":"0001104659-25-096935","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Marker Therapeutics treats first patient in Phase 1 OTS MAR-T cell study; well tolerated","event_type":"other_material","confidence":"high","bullets":["First patient dosed at 100x10^6 cells in Phase 1 RAPID study evaluating MT-401 as Off-the-Shelf product.","No treatment-related adverse events observed in first patient; safety consistent with prior MAR-T cell data.","OTS product aims to accelerate time to treatment to as fast as 72 hours using healthy donor material.","Non-dilutive funding from FDA, NIH SBIR, and CPRIT supports OTS program without affecting cash runway.","APOLLO study in lymphoma reported 66% objective response rate and durable complete responses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134002,"accession_number":"0001104659-25-082783","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Marker Therapeutics Phase 1 APOLLO data: 66% ORR in NHL; 50% CR; dose expansion cleared","event_type":"other_material","confidence":"high","bullets":["66% objective response rate in NHL patients (8/12), with 50% complete response (6/12) at doses 100-200×10^6 cells.","No dose-limiting toxicities or ICANS observed; two Grade 1 CRS events (no treatment required).","Safety Review Committee cleared 400×10^6 cells max dose for DLBCL dose expansion in CAR-T relapsed/ineligible patients.","HL patients (n=9) showed 78% ORR (7/9) with 11% CR; median 8 prior lines of therapy.","Webcast August 26, 2025 at 8:30 am ET; next data update expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134001,"accession_number":"0001104659-25-076834","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Marker Therapeutics changes auditor from Marcum to CBIZ CPAs; no disagreements","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor on August 6, 2025; CBIZ CPAs engaged for FY 2025.","Marcum's prior reports contained a going concern explanatory paragraph but no adverse opinions.","No disagreements or reportable events occurred during Marcum's tenure through 2025.","Change follows CBIZ's acquisition of Marcum's attest business effective November 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150742,"accession_number":"0001104659-25-060092","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Marker partners Cellipont for cGMP manufacturing of MT-601 for lymphoma trial","event_type":"other_material","confidence":"high","bullets":["Partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, a MAR-T cell therapy for lymphoma in Phase 1 APOLLO study.","APOLLO study previously reported 78% objective response (7/9) and 44% complete response (4/9) at 4 weeks post MT-601 infusion.","Cellipont to provide technology transfer and cGMP manufacturing services over approximately nine months to support clinical supply.","Collaboration designed to enable potential pivotal trial and commercial readiness; Cellipont facility in The Woodlands, TX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150741,"accession_number":"0001104659-25-057836","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Marker Therapeutics stockholders elect directors, approve say-on-pay, ratify auditor at 2025 annual meeting","event_type":"other","confidence":"high","bullets":["Four director nominees elected: Eansor (4.1M for), Elms (4.1M), Knobil (4.1M), Vera (4.1M); broker non-votes 2.8M.","Advisory vote on named executive officer compensation passed: 4.45M for, 343K against, 13.9K abstain.","Ratification of Marcum LLP as independent auditor for FY2025: 7.49M for, 80.8K against, 53.9K abstain.","Total shares outstanding 11.3M; 67.43% quorum (7.63M shares present or proxy)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150740,"accession_number":"0001104659-25-050771","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Marker Therapeutics: lymphodepletion improves MT-601 cell expansion; enrollment surging","event_type":"other_material","confidence":"high","bullets":["Phase 1 APOLLO study data: TCR sequencing shows MT-601 clones expanded/persisted at higher levels with lymphodepletion.","Prior data (Dec 2024): 7/9 patients (78%) objective response, 4 complete responses (44.4%); no DLTs or ICANS.","In first 5 months of 2025, enrolled and manufactured product for more patients than in all of 2024.","Company expects clinical data readout from APOLLO study later this year.","MT-601 targets lymphoma patients who relapsed after anti-CD19 CAR-T or for whom CAR-T is not an option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169680,"accession_number":"0001104659-25-029666","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics FY2024 net loss $10.7M; MT-601 78% response rate in lymphoma","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.7M for FY2024 vs $8.2M in FY2023; R&D expense $13.5M, G&A $4.2M.","Cash and equivalents $19.2M at Dec 31, 2024; funds operations into Q1 2026 without additional grants.","Phase 1 APOLLO study: MT-601 (neldaleucel) achieved 78% objective response rate (7/9) with 44.4% complete responses; well-tolerated.","Secured $13M+ in non-dilutive funding from CPRIT ($9.5M) and NIH SBIR ($2M) for pancreatic and lymphoma programs.","December 2024 private placement raised $16.1M from new and existing investors including Blue Owl, NEA, Aisling Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":349104.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169679,"accession_number":"0001104659-25-028821","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Marker Therapeutics stockholders approve issuance of 8.28M warrant shares","event_type":"other_material","confidence":"high","bullets":["At special meeting on March 21, 2025, 4,158,543 shares (38.83% of outstanding) represented.","Proposal passed: 3,483,897 for, 668,383 against, 6,263 abstained.","Approves issuance of up to 5,031,250 shares under Series A Warrants and 3,247,445 under Series B Warrants.","Total authorized warrant shares: 8,278,695, approximately 77% of 10.7M outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169676,"accession_number":"0001104659-25-020405","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K/A","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Marker Therapeutics corrects option grant date to Feb 12, 2025; awards options to CEO and directors","event_type":"other_material","confidence":"high","bullets":["CEO Dr. Juan Vera receives 50,000 stock options vesting annually over three years.","Non-employee directors David Eansor, Katherine Knobil, Steven Elms each receive 30,000 options.","Amendment corrects prior filing: grant date changed from Feb 12, 2024 to Feb 12, 2025.","All options are under the 2020 Omnibus Stock Ownership Plan and standard award agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169678,"accession_number":"0001104659-25-015224","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Marker Therapeutics grants 50,000 CEO options and 30,000 options each to three non-employee directors","event_type":"other","confidence":"high","bullets":["CEO Juan Vera awarded 50,000 stock options vesting annually over three years under 2020 Plan.","Non-employee directors David Eansor, Katherine Knobil, and Steven Elms each receive 30,000 options with same vesting.","Awards approved by Compensation Committee and Board on February 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}